FDA Cites Fresenius Kabi AG in 2026-09-22 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
At a glance: The FDA Center for Drug Evaluation and Research issued a warning letter to Fresenius Kabi AG (MARCS-CMS 733107, dated September 22, 2026) following an inspection of Fresenius Kabi USA LLC (FEI 1450022, Melrose Park, IL) conducted January 27–February 18, 2026, citing significant Current Good Manufacturing Practice violations for finished sterile injectable pharmaceuticals. The FDA documented failures to adequately investigate batch discrepancies and product failures, including endotoxin test failures associated with famotidine for injection that resulted in adverse patient events and three product recalls, and media fill failures on aseptic manufacturing lines in 2024–2025 that indicated deficient operator aseptic techniques. The FDA stated that the firm's drug products are adulterated under 21 U.S.C. 351(a)(2)(B) and warned that failure to promptly address violations may result in seizure, injunction, or other regulatory action.
Argus analysis
# FDA Warning Letter Analysis: Fresenius Kabi AG
**Company and Findings**
Fresenius Kabi AG, a global pharmaceutical manufacturer, received a warning letter dated September 22, 2026, from the FDA's Center for Drug Evaluation and Research (CDER) following an inspection of its Melrose Park, Illinois facility (January 27–February 18, 2026). The FDA documented significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals, rendering drug products adulterated under the Federal Food, Drug, and Cosmetic Act. The violations centered on inadequate investigation of batch failures, discrepancies, and deviations.
**Regulatory Citations and Implications**
The primary violation cited 21 CFR 211.192, which requires thorough investigation of unexplained batch discrepancies or specification failures. The FDA identified three critical patterns: endotoxin test failures linked to patient adverse events (including pyrogenic reactions) after famotidine injection administration; media fill failures on aseptic processing lines indicating deficient operator technique; and extrinsic biological contamination (hair) documented in at least nine instances since May 2022. These violations reflect systemic weaknesses in root cause analysis, corrective action implementation, and quality oversight rather than isolated incidents.
**Timeline and Industry Monitoring Points**
Fresenius Kabi submitted a response to the FDA Form 483 on March 11, 2026, which the agency deemed inadequate. The company must now submit a comprehensive remediation plan addressing investigation competencies, root cause evaluation protocols, CAPA effectiveness verification, and quality assurance oversight. Industry peers should monitor for public communications regarding product recalls, process line shutdowns, or management changes. Regulatory observers typically expect formal responses within 15 business days, followed by FDA compliance inspections to verify corrective actions over subsequent months.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Fresenius Kabi AG MARCS-CMS 733107 — September 22, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Reference #: 320-26-129 Product: Drugs Recipient: Recipient Name Mr. Pierluigi Antonelli Recipient Title Chief Executive Officer Fresenius Kabi AG 61346 Bad Homburg Germany (b)(4) Issuing Office: Center for Drug Evaluation and Research (CDER) United States September 22, 2026 WARNING LETTER Reference number: 320-26-129 To Mr. Antonelli: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. FDA Inspection Violations were observed and documented during an inspection of your drug manufacturing facility, Fresenius Kabi USA LLC, FDA Establishment Identifier (FEI) 1450022, at 2085 N Hawthorne Ave, Melrose Park, IL from January 27 to February 18, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your March 11, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility. 1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192). Your firm is a manufacturer of sterile injectable drug products produced primarily through aseptic processing, including but not limited to, products for intravenous (b)(4) use. You failed to adequately investigate drug pro…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Fresenius Kabi AG had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Fresenius Kabi AG as of 2026-09-29. Argus ingests new FDA enforcement records daily.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Cites Fresenius Kabi AG in 2026-09-22 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-fresenius-kabi-ag-2026-09-22-cgmp
"FDA Cites Fresenius Kabi AG in 2026-09-22 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-fresenius-kabi-ag-2026-09-22-cgmp.
Argus HQ Research. "FDA Cites Fresenius Kabi AG in 2026-09-22 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated." Digital Empire Holdings LLC. Accessed September 30, 2026. https://argushq.ai/fda/warning-letter/fda-wl-fresenius-kabi-ag-2026-09-22-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_fresenius_kabi_ag_2026_09_22_cgmp_2026,
title = {FDA Cites Fresenius Kabi AG in 2026-09-22 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-fresenius-kabi-ag-2026-09-22-cgmp},
note = {Accessed: September 30, 2026}
}